These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The efficacy of immunohistochemistry in the diagnosis of molecular genetic alterations in central nervous system gliomas: Next-generation sequencing of 212 mutations in 112 patients. Daoud EV; Chkheidze R; Yell PC; Hatanpaa KJ; Raisanen JM; Cai C Clin Neuropathol; 2022; 41(1):35-40. PubMed ID: 34672256 [TBL] [Abstract][Full Text] [Related]
6. Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH. de Biase D; Acquaviva G; Visani M; Marucci G; De Leo A; Maloberti T; Sanza V; Di Oto E; Franceschi E; Mura A; Ragazzi M; Serra S; Froio E; Bisagni A; Brandes AA; Pession A; Tallini G J Mol Diagn; 2021 Sep; 23(9):1185-1194. PubMed ID: 34186176 [TBL] [Abstract][Full Text] [Related]
7. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas. Malueka RG; Theresia E; Fitria F; Argo IW; Donurizki AD; Shaleh S; Innayah MR; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA; Dwianingsih EK Asian Pac J Cancer Prev; 2020 Nov; 21(11):3229-3234. PubMed ID: 33247679 [TBL] [Abstract][Full Text] [Related]
9. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing. Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305 [TBL] [Abstract][Full Text] [Related]
10. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927 [TBL] [Abstract][Full Text] [Related]
11. Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas: Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors. Carter JH; McNulty SN; Cimino PJ; Cottrell CE; Heusel JW; Vigh-Conrad KA; Duncavage EJ J Mol Diagn; 2017 Mar; 19(2):328-337. PubMed ID: 28042970 [TBL] [Abstract][Full Text] [Related]
12. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Shibahara I; Sonoda Y; Kanamori M; Saito R; Yamashita Y; Kumabe T; Watanabe M; Suzuki H; Kato S; Ishioka C; Tominaga T Int J Clin Oncol; 2012 Dec; 17(6):551-61. PubMed ID: 21971842 [TBL] [Abstract][Full Text] [Related]
13. Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples. Avsar T; Sursal A; Turan G; Yigit BN; Altunsu D; Cantasir K; Duyu G; Bayoumi AB; Yapicier O; Acar M; Kilic T Mol Diagn Ther; 2020 Jun; 24(3):327-338. PubMed ID: 32274701 [TBL] [Abstract][Full Text] [Related]
14. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens. Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840 [TBL] [Abstract][Full Text] [Related]
15. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499 [TBL] [Abstract][Full Text] [Related]
16. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas. Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036 [TBL] [Abstract][Full Text] [Related]
17. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747 [TBL] [Abstract][Full Text] [Related]
18. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062 [TBL] [Abstract][Full Text] [Related]
19. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501 [TBL] [Abstract][Full Text] [Related]
20. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis. Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]